Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
A. A. Rubio, V. A. Baharani, B. Dadonaite, M. Parada, M. E. Abernathy, Z. Wang, Y. E. Lee, M. Eso, J. Phung, I. Ramos, T. Chen, G. El Nesr, J. D. Bloom, P. D. Bieniasz, M. C. Nussenzweig, C. O. Barnes
The paper designs bispecific antibodies that retain neutralization activity against multiple SARS-CoV-2 variants, including Omicron subvariants.
bioRxiv · May 5, 2024 · PreprintImmunology
C. Fan, A. A. Cohen, M. Park, A. F.-H. Hung, J. R. Keeffe, P. N. Gnanapragasam, Y. E. Lee, L. M. Kakutani, Z. Wu, K. E. Malecek, J. C. Williams, P. J. Bjorkman
This study identifies cross-reactive monoclonal antibodies against conserved sarbecovirus epitopes using mosaic RBD nanoparticles and shows their neutralization potential against SARS-CoV-2 variants and animal sarbecoviruses.
bioRxiv · Jun 28, 2022Immunology
A. A. Cohen, N. A. van Doremalen, A. J. Greaney, H. Andersen, A. Sharma, T. N. Starr, J. R. Keeffe, C. Fan, J. E. Schulz, P. N. P. Gnanapragasam, L. M. Kakutani, A. P. West, G. Saturday, Y. E. Lee, H. Gao, , P. J. Bjorkman
This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.
bioRxiv · Mar 25, 2022 · PreprintMicrobiology
C. O. Barnes, T. Schoofs, P. N. P. Gnanapragasam, J. Golijanin, K. E. Huey-Tubman, H. Gruell, P. Schommers, N. Suh-Toma, Y. E. Lee, J. C. C. Lorenzi, A. Piechocka-Trocha, J. F. Scheid, A. P. West, B. D. Walker, M. S. Seaman, , P. J. Bjorkman
This paper describes a VRC01-class antibody with lower somatic mutation but comparable breadth and potency to other broadly neutralizing antibodies against HIV-1.
bioRxiv · Mar 16, 2022Immunology
Z. Wang, F. Muecksch, A. Cho, C. Gaebler, H.-H. Hoffmann, V. Ramos, S. Zong, M. Cipolla, B. Johnson, F. Schmidt, J. DaSilva, E. Bednarski, T. B. Tanfous, R. Raspe, K. Yao, , M. C. Nussenzweig
The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.
bioRxiv · Feb 1, 2022 · PreprintImmunology
C. A. Jette, A. A. Cohen, P. N. P. Gnanapragasam, F. Muecksch, Y. E. Lee, K. E. Huey-Tubman, F. Schmidt, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, A. P. West, J. R. Keeffe, P. Bjorkman, C. O. Barnes
The paper identifies two class 4 anti-RBD antibodies from COVID-19 donors that broadly neutralize zoonotic sarbecoviruses and SARS-CoV-2 variants with high potency.
bioRxiv · Apr 23, 2021Immunology
M. E. Abernathy, H. B. Gristick, J. Vielmetter, J. R. Keeffe, P. N. Gnanapragasam, Y. E. Lee, A. Escolano, R. Gautam, M. S. Seaman, M. A. Martin, M. C. Nussenzweig, P. J. Bjorkman
This study identifies an off-target antibody that displaces the HIV-1 Env fusion peptide and blocks neutralizing epitopes, providing insights for vaccine design.
bioRxiv · Mar 17, 2021Immunology
A. A. Cohen, P. N. P. Gnanapragasam, Y. E. Lee, S. Ou, L. M. Kakutani, J. R. Keeffe, C. O. Barnes, H.-J. Wu, M. Howarth, A. P. West, M. C. Nussenzweig, P. J. Bjorkman
The paper demonstrates that mosaic nanoparticles displaying multiple coronavirus RBDs induce cross-reactive and neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses in mice.
bioRxiv · Nov 17, 2020Immunology